Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation document (Audio version) (December 2007)
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Introduction and timetable
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 1. Appraisal committee
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 2. Clinical Needs
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 3. Technologies
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Appendix B
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Appendix A
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 8. Proposed date for review of guidance
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 7. Related NICE guidance
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 6. Proposed recommendations for further research
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 5. Implementation
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 4. Clinical Effectiveness
This page was last updated: 30 March 2010